Subsequent Events (Details Textual) - USD ($)					1 Months Ended	3 Months Ended
	Dec. 13, 2016	Nov. 10, 2016	Nov. 04, 2016	Nov. 03, 2016	Nov. 02, 2016	Oct. 31, 2016	Jul. 31, 2016	Dec. 15, 2014
Subsequent Event [Line Items]
Common Stock, Par or Stated Value Per Share						$ 0.001	$ 0.001
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						50,000
Finite-Lived License Agreements, Gross								$ 55,000,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Stock to Be Issued		14,327
Proceeds From Royalty Payment				$ 524,142
License Agreement Amendment Description	(i) $20,625,000 and then the Residual Royalty thereafter or (ii) $26,250,000, if Adapt has received in excess of $25,000,000 of cumulative Net Sales for any two consecutive fiscal quarters during the period from October 1, 2016 through September 30, 2017 from the sale of NARCAN (the Earn Out Milestone), and then the Residual Royalty thereafter.
Residual Royalty Defined In Purchase Agreement	(i) if the Earn Out Milestone is paid, then SWK shall receive 10% of all Royalties; provided, however, if no generic version of NARCAN is commercialized prior to the sixth anniversary of the Closing, then SWK shall receive 5% of all Royalties after such date, and (ii) if the Earn Out Milestone is not paid, then SWK shall receive 7.86% of all Royalties; provided, however, that if no generic version of NARCAN is commercialized prior to the sixth anniversary of the Closing, then SWK shall receive 3.93% of all Royalties after such date.
Purchase Agreement Grants Description	(i) the right to receive the statements produced by Adapt pursuant to Section 5.6 of the Adapt Agreement and (ii) the right, to the extent possible under the Purchase Agreement, to cure any breach of or default under any Product Agreement by the Company.
Upfront Purchase Price Received Under Purchase Agreement	$ 13,750,000
Milestone Payment Receivable Under Purchase Agreement	$ 3,750,000
Indemnification Obligations Under Purchase Agreement Description	Absent fraud by the Company, the Company’s indemnification obligations under the Purchase Agreement shall not exceed, individually or in the aggregate, an amount equal to the Purchase Price plus an annual rate of return of 12% (compounded monthly) as of any date of determination, with a total indemnification cap not to exceed 150% of the Purchase Price, less all Royalties received by SWK, without duplication, under the Purchase Agreement prior to and through resolution of the applicable claim.
Subsequent Event [Member] | Consultant [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Value, Issued for Services					$ 1,000
Common Stock, Par or Stated Value Per Share					$ 0.001
Subsequent Event [Member] | Thomas [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			35,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price			$ 10.00
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term			5 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights			vest as follows: (i) 11,667 shares vest upon the uplisting of the Company to the NASDAQ Stock Market; (ii) 11,667 shares vest upon the cumulative funding of the Company of or in excess of $5,000,000 by institutional investors starting from November 4, 2016; and 11,666 shares vest upon the first submission of a New Drug Application to the U.S. Food and Drug Administration for one of Companys products by Company itself or a Company licensee.